New Stock Outlook | Production Capacity Ranks First in Asia, but Profit Anxiety is Hard to Conceal: How Likely is Wei Kang Probiotics to Succeed in Listing on the Hong Kong Stock Exchange?

With a market size of 140 billion and a five-year compound growth rate of nearly 10%, this is the report card that the Chinese probiotics industry handed in for 2025. However, on this high-growth golden track, the development and professional application of independent strains are the real breakthroughs in the second half. As the industry evolves from a single scene of "lactic acid drinks" to layouts in various fields such as health products, food, and even biopharmaceuticals, Weikang Probiotics chose to go public in Hong Kong at this time. Its confidence does not only come from the dividends of the trillion-level large health market, but also from the firm belief in China's local probiotics transitioning from a "follower" to a "leader" in technology. Can this enterprise, focusing on the heavy-weight development and industrialization of strains, tell a new story about "Chinese strains" in the Hong Kong stock market? With production capacity ranking first in Asia, building a "strain + preparation" moat The hidden pain of the Chinese probiotics market lies in the long-term absence of core strains. Despite a variety of end products, a report from Sunpu Consulting pointed out that China's industrial core strains are dependent on imports by over 70%. Under the patent blockade of international giants such as DuPont and Chr. Hansen, domestic enterprises often play the role of "raw material carriers," with meager profits and constraints. The rise of Weikang Probiotics aims to overturn this market dominated by foreign capital and reshape the global discourse of "Chinese strains." According to a report from Frost & Sullivan, by 2025, Weikang Probiotics has made it to the top three in the global probiotic original powder production and first in Asia. This is not just a numerical leap, but also solid evidence of its dual-engine efforts in "R&D + industrialization." By building a vast library of independent strains and solving mass production challenges, Weikang Probiotics is taking back the leadership of the probiotics industry from foreign giants. As a typical "specialized and innovative" enterprise, Weikang Probiotics' core competitiveness lies in its integration of the entire industry chain from strain discovery, functional verification to large-scale production. The company currently has a library of over 40,000 strains, including core strains with independent intellectual property rights such as animal bifidobacteria subsp. BLa80 and Lactobacillus rhamnosus LRa05. These strains are not just laboratory exhibits, but have already achieved high activity and stability in industrialized mass production. It is understood that after storing its core strains at room temperature for 24 months, the survival rate of live cells can still be maintained at over 60%, with a count of over 10 trillion CFU/g for multiple strains. This technological barrier of transforming microbial resources into stable industrial products is Weikang Probiotics' strongest moat. Currently, the company's production bases in Suzhou and Luohe have the capacity to produce 700 tons of probiotic original powder and over 5,000 tons of probiotic preparations annually. This strong manufacturing capability allows it to quickly meet the diverse needs of downstream sectors such as food, dairy products, agriculture, and biopharmaceuticals. Steady revenue growth, but profitability quality remains to be verified Looking at Weikang Probiotics' financial statements, we see a typical portrait of a high-growth enterprise in an expansion phase: rapidly increasing revenue scale, but with fluctuations in profitability quality in some indicators. It is worth noting that in recent years, Weikang Probiotics' revenue growth momentum has been quite strong. From 2023 to 2025, the company's total revenue increased from 496 million yuan to 701 million yuan, with a significant compound annual growth rate. This growth momentum is mainly derived from two aspects: the stability of the Greater China market and the explosion in overseas markets. Importantly, in 2025, the revenue share from overseas markets reached 40.2%, indicating initial success in its international expansion. In terms of product structure, probiotic powders and preparations for human health are the revenue anchors, and there are also stable sources of income in the dairy and agricultural sectors. However, behind the high revenue growth, the trend of profitability is not optimistic. Although the company has maintained profitability for three years and adjusted net profit reached 107 million yuan in 2025, an increase from 2024, there are concerns when observing the change in gross profit margin. During the reporting period, the company's gross profit margin decreased from 49.7% in 2023 to 47.5% in 2025. At the same time, the proportion of sales and marketing expenses and research and development costs are increasing. This indicates that while the company has achieved revenue growth by expanding its scale, the pressure on the cost side to maintain market share and research and development investment is also increasing simultaneously. This "increase in revenue without increasing profit" marginal effect is a key point that investors must focus on when evaluating its financial health. However, from the perspective of cash flow, the net cash flow generated from operating activities rebounded to 217 million yuan in 2025, showing that its core business still has strong blood-making ability, providing a solid financial foundation for the company's continuous investment in the future. Opportunities and challenges coexist in a high-growth industry demand Looking ahead to the future from the perspective of 2026, Weikang Probiotics faces unprecedented interwoven opportunities and challenges. The industry outlook is an important support for the valuation narrative of Weikang Probiotics. According to Frost & Sullivan data, the global probiotic original powder market size is expected to increase from 32.64 billion US dollars in 2025 to 48.21 billion US dollars in 2030, with a compound annual growth rate of 8.1%. China's growth is even more outstanding, expected to increase from 482.9 million US dollars to 794.2 million US dollars, with a compound annual growth rate of 10.5%, and is expected to exceed 1.4 billion US dollars by 2035. The growth drivers include increased health awareness, accelerated aging, expanded application scenarios, and policy dividends from the inclusion of biomanufacturing in the "14th Five-Year Plan." As for development risks, they mainly focus on external uncertainties. The prospectus specifically warns of the risks posed by changes in the international trade environment. With the company's overseas revenue approaching four-tenths, factors such as geopolitical conflicts, trade protectionism, and export controls could become "speed bumps" for its performance growth. In addition, although the probiotics industry as a whole has a promising growth rate, competition is intensifying. The advantages of domestic and foreign competitors in brand awareness, channel coverage, as well as the risk of fluctuating raw material prices, may erode Weikang Probiotics' profit margins. Particularly as a company planning to go public on the Hong Kong Stock Exchange, how to clearly explain to international investors its unique barriers on the "Chinese strains" track will directly determine its valuation logic. Nevertheless, Weikang Probiotics' future blueprint remains clear and grand. According to the disclosure in the prospectus, the funds raised through the IPO will mainly be used to expand production capacity, strengthen R&D capabilities, and enhance international brand influence. Specifically, the company plans to further consolidate its production capacity advantage through expanding its Suzhou production base over the next three years, while investing funds to upgrade high-end laboratory facilities to develop more beneficial microbial products for agriculture and new formulations. In terms of globalization strategy, Weikang Probiotics is not satisfied with just being a raw material supplier, but is attempting to directly reach end consumers by establishing a wide international marketing network and building a globally influential Chinese probiotics brand. In conclusion, Weikang Probiotics' IPO application is an important signal for Chinese domestic probiotics companies to enter the international capital market. The company has established verifiable barriers in the independent development and industrialization of strains, and the continuous increase in overseas revenue shows its international competitiveness. However, the downward trend in gross profit margin, fluctuations in net profit, pressure from new production capacity, and the gap in scale with international giants are all realities that investors cannot ignore. In the probiotics market worth billions, Weikang has proven its ability to run in the forefront, but to grow from a "follower" to a "leader," it requires a long-term balance between profit margin, brand strength, and globalization strategy.